- Home
- EYPT
as 06-26-2025 12:35pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 484.4M | IPO Year: | 2005 |
| Target Price: | $24.75 | AVG Volume (30 days): | 906.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.91 - $13.98 | Next Earning Date: | 08-06-2025 |
| Revenue: | $56,042,000 | Revenue Growth: | 12.04% |
| Revenue Growth (this year): | -3.95% | Revenue Growth (next year): | -57.06% |
Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zaderej Karen L. | EYPT | Director | May 16 '25 | Buy | $5.90 | 10,000 | $59,000.00 | 31,500 | |
| Zaderej Karen L. | EYPT | Director | May 14 '25 | Buy | $5.45 | 10,000 | $54,450.00 | 31,500 |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target
GlobeNewswire
10 days ago
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
a month ago
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
MT Newswires
a month ago
Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating
GlobeNewswire
a month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
EyePoint Announces Participation at Upcoming Investor Conferences
Simply Wall St.
2 months ago
New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.